DaVita (DVA) Expected to Announce Earnings on Thursday

DaVita (NYSE:DVA - Get Free Report) is expected to post its Q1 2025 quarterly earnings results before the market opens on Thursday, May 1st. Analysts expect DaVita to post earnings of $1.75 per share and revenue of $3.22 billion for the quarter. DaVita has set its FY 2025 guidance at 10.200-11.300 EPS.

DaVita (NYSE:DVA - Get Free Report) last issued its quarterly earnings results on Thursday, February 13th. The company reported $2.24 EPS for the quarter, topping analysts' consensus estimates of $2.14 by $0.10. DaVita had a net margin of 7.31% and a return on equity of 115.48%. On average, analysts expect DaVita to post $11 EPS for the current fiscal year and $13 EPS for the next fiscal year.

DaVita Trading Up 0.7 %

DaVita stock traded up $0.95 during trading on Tuesday, reaching $141.45. The company had a trading volume of 611,789 shares, compared to its average volume of 839,190. DaVita has a 12-month low of $131.27 and a 12-month high of $179.60. The stock's 50 day moving average price is $146.13 and its two-hundred day moving average price is $155.01. The firm has a market capitalization of $11.32 billion, a price-to-earnings ratio of 13.17, a PEG ratio of 1.07 and a beta of 1.04. The company has a debt-to-equity ratio of 23.18, a quick ratio of 1.21 and a current ratio of 1.26.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the stock. StockNews.com upgraded shares of DaVita from a "hold" rating to a "buy" rating in a report on Friday. Barclays boosted their target price on shares of DaVita from $164.00 to $169.00 and gave the company an "equal weight" rating in a report on Tuesday, February 18th. Cowen restated a "hold" rating on shares of DaVita in a report on Tuesday, February 18th. Finally, Sanford C. Bernstein set a $184.00 target price on shares of DaVita in a report on Friday, February 21st. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $166.33.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.